GLPG3667 Meets Primary Endpoint in Dermatomyositis, Misses in SLE Phase 3 Trials Alex Hillenbrand

Published Date: 14 Jan 2026

Topline results show GLPG3667 met its primary endpoint in a phase 3-enabling dermatomyositis trial but missed in systemic lupus erythematosus.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

2.

Do Anatomy Atlases Reflect Social Inequalities?

3.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.

4.

Some triple negative breast cancers might be avoided by longer breastfeeding

5.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot